Affiliation:
1. The Medicines Company, San Diego, California, USA
Abstract
Vaborbactam is a novel beta-lactamase inhibitor with activity against important beta-lactamases, in particular, serine carbapenemases, and is currently approved in combination with meropenem as Vabomere for the treatment of complicated urinary tract infections, including pyelonephritis. This combination is highly active against Gram-negative pathogens, especially
Klebsiella pneumoniae
carbapenemase (KPC)-producing carbapenem-resistant
Enterobacteriaceae
.
Funder
HHS | Biomedical Advanced Research and Development Authority
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference26 articles.
1. State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
2. Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore
3. Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans
4. Comparison of the Activity of a Human Simulated, High-Dose, Prolonged Infusion of Meropenem against
Klebsiella pneumoniae
Producing the KPC Carbapenemase versus That against
Pseudomonas aeruginosa
in an
In Vitro
Pharmacodynamic Model
5. Walker R, Andes D, Conklin J, Ebert S, Craig WA. 1994. Pharmacodynamic activities of meropenem in an animal infection model, abstr A91. Abstr 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL.
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献